Cellectar Biosciences, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Cellectar is a clinical-stage biopharmaceutical company developing cancer therapies using its phospholipid drug conjugate platform. It reported no revenue; its results reflect research and development and administrative spending.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $4.50 million | $4.63 million | $8.39 million | $9.26 million |
| General and administrative | $2.94 million | $1.40 million | $5.19 million | $3.13 million |
| Total expenses | $7.44 million | $6.03 million | $13.58 million | $12.39 million |
| Net loss | $7.44 million | $6.03 million | $13.57 million | $12.39 million |
| Net loss per share | $1.22 | $1.14 | $2.22 | $2.45 |
- Cash and cash equivalents were $24.81 million at June 30, 2022, down from $35.70 million at year-end 2021. Six-month operating cash use was $10.80 million, compared with $11.63 million in 2021. Investing cash use was $0.10 million; there were no financing proceeds in the period.
- Current assets were $25.29 million and current liabilities $5.61 million. Total liabilities were $5.70 million, primarily accounts payable and accrued liabilities of $5.46 million and lease liabilities. The filing shows no borrowings. Accumulated deficit was $164.47 million.
- Margins are not meaningful because the company reported no revenue. The filing does not provide a clear operating-margin measure.
Changes and notable developments
- Second-quarter R&D expense decreased 3% year over year, principally because of the timing of pivotal-trial activity; manufacturing, personnel and preclinical costs partly offset the reduction. Six-month R&D decreased 9% for similar timing reasons.
- G&A increased 110% in Q2 and approximately 66% for the six months, driven by professional fees and personnel costs, including stock-based compensation, as well as travel. Total six-month expenses and net loss increased year over year.
- At the June 30 balance-sheet date, common shares outstanding were 6,110,123. A 1-for-10 reverse split became effective July 21, 2022 to support Nasdaq continued-listing compliance; financial statements give it retroactive effect.
Outlook, risks and contingencies
- Management said available cash was adequate for basic budgeted operations into the third quarter of 2023. Continuing operations beyond that point depend on additional capital through equity or debt issuance, a strategic transaction or another source. The company disclosed substantial doubt about its ability to continue as a going concern within one year of issuance of the financial statements.
- The CLOVER-WaM pivotal study of iopofosine for relapsed/refractory Waldenstrom’s macroglobulinemia had enrollment delays tied to COVID-19-related site resourcing and patient concerns. In April 2022, an independent data monitoring committee recommended continuing the trial after its interim safety and futility review of the first 10 patients.
- Iopofosine remains in clinical development, including studies in multiple myeloma and pediatric cancers. Reported adverse events include fatigue and cytopenias; the filing notes that fatalities due to infection have occurred in treated patients. Clinical results cited are not guarantees of future outcomes.
- The company expects operating losses to continue and depends on clinical progress, financing availability and third parties, including its sole iopofosine supplier. Other disclosed uncertainties include COVID-19 effects and Nasdaq listing requirements.
- Cellectar’s lawsuit against two former associates alleges diversion of intellectual property. The company seeks damages and injunctive relief; it says the disputed IP does not directly affect current iopofosine clinical studies but may affect future research, development or commercialization. Management did not expect ordinary-course legal matters to materially affect the financial statements.
- Management assessed disclosure controls as effective at June 30, 2022 and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether the company secures financing, and how its cash runway compares with actual spending and trial needs.
- Enrollment pace, interim and eventual results, safety findings, and regulatory plans for CLOVER-WaM and other iopofosine studies.
- Whether COVID-19 or supply constraints further delay clinical programs or increase costs.
- Nasdaq continued-listing compliance following the reverse split, and potential dilution from future financing, warrants and stock awards.
- The status and potential financial or strategic impact of the disputed intellectual-property litigation.